###begin article-title 0
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 106 141 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 143 146 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 222 225 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 385 388 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 665 668 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1154 1161 <span type="species:ncbi:9606">patient</span>
###xml 1288 1291 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Macrophages in the central nervous system (CNS) and other tissues are an important cellular reservoir for human immunodeficiency virus type 1 (HIV) infection, particularly in the later stages of disease. Macrophage-tropic HIV strains have an enhanced capacity to enter cells expressing low levels of CD4 through mechanisms that are not well understood. Here, we use a panel of primary HIV envelopes from brain and lymphoid tissues to examine the relationship between neutralization sensitivity to reagents targeting the CD4 binding site and virus entry into macrophages. Neutralization assays using pseudotyped viruses showed an association between the capacity of HIV to enter macrophages and increased sensitivity to the broadly neutralizing monoclonal antibody (mAb) b12, which recognizes a conserved epitope overlapping the CD4 binding site, but not sensitivity to soluble CD4 (sCD4) or b6, a non-neutralizing CD4 binding site mAb. Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum. These findings suggest that exposure of the b12 epitope, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4. These findings suggest overlap between specific gp120 determinants in or near the b12 epitope and those conferring macrophage tropism.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 831 832 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 37 40 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 286 289 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 946 949 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Human immunodeficiency virus type 1 (HIV) infects tissue macrophages, microglia, and other mononuclear phagocytes, which represent an important cellular reservoir for viral replication and persistence in brain and other macrophage-rich tissues (i.e., lung, gut, and bone marrow) [1-3]. HIV entry into cells is initiated by interaction between the envelope glycoprotein (Env) surface subunit gp120 and CD4, which induces a conformational change in gp120 that exposes the coreceptor binding site [4]. The interaction of CD4-bound gp120 with a coreceptor, usually CCR5 or CXCR4, triggers conformational changes in gp120 and the transmembrane subunit gp41 that enable fusion and virus entry. CCR5 is the primary coreceptor used for infection of macrophages [4-7]. CCR5 usage is neither necessary nor sufficient for macrophage tropism [8], however, suggesting that determinants other than those that specify coreceptor usage influence the capacity of HIV to replicate in macrophages.
###end p 4
###begin p 5
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 107 110 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 276 279 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 511 514 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Macrophages express lower levels of CD4 compared to CD4+ T-lymphocytes. Previous studies demonstrated that HIV macrophage tropism is associated with an enhanced capacity to use low levels of CD4 for fusion and entry [9-14]. We previously identified amino acid variants in the HIV Env that increase viral tropism for macrophages by enhancing gp120-CD4 affinity (N283 in the C2 region) or exposure of the CD4 binding site (loss of an N-linked glycosylation site at position 386 in the V4 region) [9,10]. However, HIV can also acquire an enhanced ability to enter macrophages by additional mechanisms that are not well defined.
###end p 5
###begin p 6
###xml 82 90 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 130 133 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 345 348 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The HIV envelope glycoproteins are the primary target for neutralizing antibodies in vivo [15,16]. The antibody response to acute HIV infection develops rapidly, and evolves concurrently with viral diversity during the course of disease, exerting strong selection pressure on viral evolution and leading to emergence of neutralization-resistant HIV variants [17,18]. The ability to generate neutralizing antibodies diminishes during disease progression, reflecting progressive loss of CD4 T-cell help and B-cell dysfunction.
###end p 6
###begin p 7
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 193 221 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 223 227 <span type="species:ncbi:12721">SHIV</span>
###xml 252 267 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 405 408 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 633 636 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 699 702 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 968 971 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV isolates that replicate efficiently in macrophages and microglia frequently exhibit increased sensitivity to neutralizing antibodies [11-13,19,20]. Consistent with these findings, a simian-human immunodeficiency virus (SHIV) isolated from infected rhesus macaques with neurological disease exhibited enhanced macrophage tropism together with increased sensitivity to neutralizing antibodies [21]. The HIV Env amino acid variant D386, which eliminates an N-linked glycosylation site and increases exposure of the conserved broadly neutralizing monoclonal antibody (mAb) b12 epitope overlapping the CD4 binding site, also enhances HIV macrophage tropism [10,22,23]. Previous studies reported that HIV macrophage tropism correlates with increased neutralization sensitivity to mAbs and other reagents that block Env-CD4 interactions but not with sensitivity to other entry inhibitors [22,23]. Collectively, these findings suggest that an association between enhanced HIV entry into macrophages and increased sensitivity to reagents targeting the CD4 binding site.
###end p 7
###begin p 8
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 51 54 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 255 258 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 382 385 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 395 402 <span type="species:ncbi:9606">patient</span>
###xml 675 678 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 688 695 <span type="species:ncbi:9606">patient</span>
###xml 855 858 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Here, we use a panel of viruses expressing primary HIV Envs from brain and lymphoid tissues [9,10,14] to further examine the association between neutralization sensitivity to reagents targeting the CD4 binding site and macrophage tropism. The capacity of HIV to enter macrophages correlated with neutralization sensitivity to the CD4 binding site mAb b12 and a broadly neutralizing HIV-infected patient serum, but not sensitivity to soluble CD4 (sCD4) or mAb b6, another mAb that targets the CD4 binding site. The loss of an N-linked glycosylation site at position 386 enhanced macrophage tropism together with sensitivity to mAb b12, but not sensitivity to sCD4, mAb b6, or HIV-infected patient serum. These findings suggest that exposure of the b12 epitope overlapping the CD4 binding site, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4.
###end p 8
###begin title 9
Findings
###end title 9
###begin p 10
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 877 878 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 992 996 992 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 1008 1012 1008 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 1045 1046 1045 1046 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1442 1444 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 115 118 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 388 391 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 663 666 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 676 683 <span type="species:ncbi:9606">patient</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
###xml 820 823 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 887 890 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 974 977 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1200 1203 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1281 1286 <span type="species:ncbi:9606">human</span>
###xml 1393 1398 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1406 1411 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We previously demonstrated that loss of an N-linked glycosylation site at position 386 in the V4 region of primary HIV Envs increases exposure of the b12 epitope and enhances macrophage tropism [10]. To better understand the relationship between macrophage tropism and sensitivity to reagents targeting the CD4 binding site, we used a panel of viruses containing CCR5-tropic (R5) primary HIV Envs cloned directly from brain and lymphoid tissues [9,10,14] to determine neutralization sensitivity to sCD4 and mAbs b12 and b6, which recognize neutralizing and non-neutralizing epitopes overlapping the CD4 binding site [24], respectively, and a broadly-neutralizing HIV-infected patient serum (Table 1). Env genes cloned into pCR3.1 from primary virus isolates or autopsy brain and lymphoid tissues from AIDS patients with HIV-associated dementia (HAD) were described previously [9,14,19]. HIV luciferase reporter viruses were generated by cotransfection of 293T cells with an HIV provirus with env deleted and nef replaced by luciferase (pNL4-3env-luc,) and pCR3.1-Env as described [19]. Cf2 cells [19] used as target cells for neutralization assays were cotransfected with pcDNA3-CD4 and pcDNA3-CCR5. HIV luciferase reporter viruses were incubated with a range of concentrations of human monoclonal Abs (mAbs), soluble CD4 (sCD4; Immunodiagnostics, Inc., Woburn, MA), or a broadly neutralizing HIV-1 serum (HIV-1 neutralizing serum (serum 2; [25]) obtained from L. Vujcic through the AIDS Research and Reference Reagent Program) 1 h prior to infection of Cf2 cells transiently expressing CD4 and CCR5. Cells were harvested 48 h post infection and assayed for luciferase activity.
###end p 10
###begin p 11
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 137 140 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 150 157 <span type="species:ncbi:9606">patient</span>
Neutralization sensitivity of primary HIV-1 Envs with variable macrophage tropism to gp120 mAbs, soluble CD4, and a broadly neutralizing HIV-infected patient serum
###end p 11
###begin p 12
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a FL, frontal lobe (brain); LN, lymph node; SP, spleen
###end p 12
###begin p 13
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
b Luciferase activity in monocyte-derived macrophages (MDM) infected with pseudotyped luciferase-expressing reporter viruses [10,14].
###end p 13
###begin p 14
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 217 219 215 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 47 50 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 60 67 <span type="species:ncbi:9606">patient</span>
c mAb (mug/ml), soluble CD4 (sCD4; mug/ml), or HIV-infected patient serum (PS; reciprocal serum dilution) concentration at which luciferase expression was reduced by 50% compared to infection in the absence of mAb (IC50).
###end p 14
###begin p 15
###xml 249 263 249 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A, C, D, F; A</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 558 563 558 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B, E</xref>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 25 28 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 130 133 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 143 150 <span type="species:ncbi:9606">patient</span>
###xml 523 526 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Viruses pseudotyped with HIV Envs that mediate high levels of entry into macrophages had increased sensitivity to mAb b12 and the HIV-infected patient serum compared to viruses expressing Envs that mediate low levels of entry in macrophages (Figure 1A, C, D, F; A and 1C, R = -0.5944, p = 0.0093 and R = -0.5021, p = 0.034, respectively, Spearman correlation; 1D and 1F, p = 0.022 and 0.034, respectively, Mann-Whitney test). In contrast, sensitivity to sCD4 or the non-neutralizing mAb b6 did not correlate with levels of HIV entry into macrophages (Figure 1B, E, p = 0.9141; and data not shown). Furthermore, there was no correlation between neutralization sensitivity to mAb b12 and neutralization sensitivity to sCD4 (p = 0.3279; Additional file 1). These results suggest that macrophage tropism is associated with increased sensitivity to mAb b12, but not sensitivity to sCD4 or the non-neutralizing CD4 binding site mAb b6. Thus, macrophage tropism was associated with increased exposure of the b12 epitope overlapping the CD4 binding site, rather than exposure of the CD4 binding site per se.
###end p 15
###begin p 16
###xml 0 144 0 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Enhanced HIV entry into macrophages is associated with sensitivity to neutralizing mAb b12 and a broadly neutralizing HIV-infected patient serum</bold>
###xml 728 730 728 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1333 1334 1333 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1395 1397 1395 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1398 1400 1398 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1582 1584 1582 1584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 1584 1585 1584 1585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 9 12 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 118 121 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 131 138 <span type="species:ncbi:9606">patient</span>
###xml 146 149 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 203 206 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
###xml 404 409 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 423 430 <span type="species:ncbi:9606">patient</span>
###xml 889 892 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1171 1176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Enhanced HIV entry into macrophages is associated with sensitivity to neutralizing mAb b12 and a broadly neutralizing HIV-infected patient serum. HIV luciferase reporter viruses pseudotyped with primary HIV Envs cloned directly from brain, spleen, or lymph node tissues from AIDS patients with HAD were incubated with a range of concentrations of human mAb b12 (A and D), soluble CD4 (sCD4; B and E), or HIV-1 neutralizing patient serum (PS; C and F) 1 h prior to infection of Cf2 cells transiently expressing CD4 and CCR5. Cells were harvested 48 h post infection and assayed for luciferase activity. (A, B, C) The concentrations at which luciferase expression was reduced by 50% compared to infection in the absence of mAb (IC50) were calculated and plotted as a function of MDM entry [10,14]. R and p values were determined by Spearman correlation. (D, E, F) b12, sCD4, and PS IC50s of HIV Envs with low to intermediate MDM infectivity (< median; median = 16,658 relative luciferase units) were compared to Envs with intermediate to high MDM infectivity (> median). Monocyte-derived macrophages (MDM) were isolated from peripheral blood mononuclear cells from healthy HIV-1-negative donors by plastic adherence and cultured in RPMI 1640 medium supplemented with 10% FBS, and 10 ng/ml macrophage colony stimulating factor (M-CSF) [8]. The MDM entry and sequence data were reported previously [10,14]. Env clones containing either the N386 or D386 variant are indicated by closed and open symbols, respectively. MDM were prepared as above in 48-well plates and infected with 2 x 104 3H cpm RT units of Env pseudotyped virus stock. Cells were lysed 6 days post-infection and assayed for luciferase activity. Significant differences between groups (p < 0.05, Mann-Whitney test) are indicated by a *.
###end p 16
###begin p 17
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 894 895 894 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 1056 1057 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1066 1068 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 1373 1375 1373 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 507 510 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 520 527 <span type="species:ncbi:9606">patient</span>
###xml 1022 1025 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1035 1042 <span type="species:ncbi:9606">patient</span>
Elimination of an N-linked glycan at position 386 in the macrophage-tropic primary HIV Envs YU2 and JRFL enhances entry into macrophages by 200% and 49%, respectively (Table 1, Figure 2A and [10]). To determine whether removal of the N-linked glycan at position 386 also influences sensitivity to b12 or other reagents that target the CD4 binding site, we investigated neutralization of viruses expressing YU2 and JRFL wild-type and N386D mutant Envs with mAbs b12 and b6, sCD4 and the broadly neutralizing HIV-infected patient serum. The N386D change in both YU2 and JRFL resulted in a 2-fold increase in sensitivity to neutralization by mAb b12 compared to that of the wild-type parental Envs (Table 1 and Figure 2B). The N386D change in YU2 resulted in increased sensitivity to sCD4, whereas the N386D change in JRFL decreased sCD4 sensitivity compared to the wild-type parental Envs (Table 1 and Figure 2C). YU2 and JRFL wild-type and N386D mutant viruses had similar sensitivities to neutralization by mAb b6 and the HIV-infected patient serum (Table 1, Figure 2D, and data not shown). These results are consistent with our previous study in which the reverse mutation D386N, which restored the N-linked glycan at position 386 in the macrophage-tropic UK1br and Macs2br13 Envs, decreased sensitivity to neutralization by mAb b12 along with replication in macrophages [10].
###end p 17
###begin p 18
###xml 0 132 0 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Loss of an N-linked glycan at position 386 in primary HIV Envs enhances macrophage tropism and neutralization sensitivity to mAb b12</bold>
###xml 824 826 824 826 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 460 465 <span type="species:ncbi:9606">human</span>
###xml 494 499 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 513 520 <span type="species:ncbi:9606">patient</span>
Loss of an N-linked glycan at position 386 in primary HIV Envs enhances macrophage tropism and neutralization sensitivity to mAb b12. (A) MDM were infected with luciferase-expressing reporter viruses expressing wild-type or N386D mutant Envs. Cells were lysed 6 days post-infection and analyzed for luciferase activity. (B, C, D) Luciferase-expressing reporter viruses expressing wild-type or N386D mutant Envs were incubated with a range of concentrations of human mAb b12 (B), sCD4 (C), or a HIV-1 neutralizing patient serum (PS; D) 1 h prior to infection of Cf2 cells transiently expressing CD4 and CCR5. Cells were harvested 48 h post infection and assayed for luciferase activity. Data are expressed as the concentrations at which luciferase expression was reduced by 50% compared to infection in the absence of mAb (IC50). Error bars represent standard deviations.
###end p 18
###begin p 19
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 346 349 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 521 528 <span type="species:ncbi:9606">patient</span>
Our findings demonstrate an association between the capacity of HIV to enter macrophages (i.e., macrophage tropism) and neutralization sensitivity to the CD4 binding site mAb b12, but not sensitivity to the non-neutralizing mAb b6 or sCD4. Furthermore, we show that loss of an N-linked glycosylation site at position 386 in the macrophage-tropic HIV YU2 and JRFL Envs enhances macrophage tropism along with neutralization sensitivity to b12, but not neutralization sensitivity to sCD4, b6, or a broadly neutralizing AIDS patient serum. These findings suggest overlap between specific gp120 determinants in or near the b12 epitope and those conferring macrophage tropism.
###end p 19
###begin p 20
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 884 887 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CD4, b12, and b6 have overlapping binding sites on gp120 [24,26]. The b12 mAb recognizes a conserved epitope on the neutralizing face of gp120 overlapping the CD4 binding site, while b6 recognizes a different epitope that partially overlaps the binding sites for b12 and CD4 [24]. The initial Env-CD4 interaction readily dissociates, and conformational changes in Env induced by CD4 binding increase the stability of the Env-CD4 complex before subsequent structural rearrangements allow coreceptor binding [26,27]. b12 contact occurs at the exposed surface on the outer domain of gp120 that is initially recognized by CD4 [26]. Furthermore, b12 is the only antibody that targets the CD4 binding site and also recognizes Env in the CD4-bound, stabilized conformation adopted before coreceptor binding [26]. These observations support the idea that exposure of the b12 epitope enhances HIV entry into macrophages, which express low levels of CD4 compared to T-cells, possibly by exposing a region on the outer domain of gp120 initially recognized by CD4.
###end p 20
###begin p 21
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 36 39 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 564 567 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The loss of a glycosylation site at HIV Env position 386 increases exposure of the b12 epitope [10,22,28], probably due to loss of steric hindrance, and also enhances macrophage tropism in a strain-dependent manner [10]. Loss of a glycosylation site at 386 does not predict b12 sensitivity [10,22,28], however, suggesting that other Env determinants influence exposure of the b12 epitope. Duenas-Decamp et al. showed that an arginine at position 373 in the C3 region, proximal to the CD4 binding site, increased resistance to b12 neutralization [22]. However, the HIV Envs in the present study all have methionine or threonine at position 373, and b12 neutralization did not correlate with amino acid differences at this position (data not shown). Thus, the influence of amino acid changes at position 373 on exposure of the b12 epitope is highly strain-dependent.
###end p 21
###begin p 22
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1136 1143 1136 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1503 1505 1503 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1506 1508 1506 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 143 146 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 238 241 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
###xml 427 430 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 511 514 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 554 557 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 874 877 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 887 895 <span type="species:ncbi:9606">patients</span>
###xml 1274 1277 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1313 1316 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1426 1429 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We found that a majority of macrophage-tropic HIV Envs are sensitive to b12 neutralization. A recent study demonstrated that early transmitted HIV variants replicate in T-cells but have relatively low capacity to replication in MDM [29]. HIV viruses isolated from late-stage AIDS patients have enhanced macrophage tropism together with increased neutralization sensitivity to b12 compared to viruses isolated from asymptomatic HIV-infected individuals [30]. Anti-CD4 binding site antibodies are generated after HIV infection, and can be detected in most HIV-infected individuals [31-33]. Broader and more potent neutralizing antibody responses are often due to the presence of neutralizing antibodies targeting the CD4 binding site [31-33]. However, only rare individuals develop broadly neutralizing anti-CD4 binding site antibodies, so b12-like antibodies are uncommon in HIV-infected patients. The neutralizing activity of sera from long-term nonprogressors is partially attributable to the presence of antibodies that target the CD4 binding site [32,34], suggesting these antibodies may play a role in controlling viral replication in vivo. Neutralizing antibody responses that target the b12 binding site may exert negative selection pressure against macrophage-tropic HIV variants until the later stages of HIV disease. The brain may be a site for emergence and persistence of neutralization-sensitive macrophage-tropic HIV variants, particularly in the setting of a weak humoral immune response [35,36].
###end p 22
###begin p 23
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 33 36 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 339 342 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 795 798 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In conclusion, macrophage-tropic HIV strains play a role in the establishing long-lived cellular reservoirs in macrophage-rich tissues that include brain, lung, gut, and bone marrow [1-3]. Furthermore, macrophages are the principal source of virus after CD4+ T cells are depleted [37]. In this study, we demonstrate an association between HIV macrophage tropism and neutralization sensitivity to the CD4 binding site mAb b12. In contrast, there was no association with neutralization sensitivity to the non-neutralizing CD4 binding site mAb b6 or sCD4. These findings suggest overlap between specific gp120 determinants that increase exposure of the b12 epitope and those conferring macrophage tropism. Future studies will be important to better understand immune selection pressures that drive HIV evolution towards variants with enhanced macrophage tropism, and the role of neutralizing antibodies that target the CD4 binding site in these processes.
###end p 23
###begin title 24
Competing interests
###end title 24
###begin p 25
The authors declare that they have no competing interests.
###end p 25
###begin title 26
Authors' contributions
###end title 26
###begin p 27
R.L.D. and D.G. designed research; R.L.D. and E.R.T performed research; R.L.D. and D.G. analyzed data; and R.L.D. and D.G. wrote the paper.
###end p 27
###begin title 28
Supplementary Material
###end title 28
###begin title 29
Additional file 1
###end title 29
###begin p 30
###xml 0 121 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Supplementary Figure. HIV Env neutralization sensitivity to mAb b12 does not correlate neutralization sensitivity to sCD4</bold>
###xml 523 525 523 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 539 541 539 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 579 581 579 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 633 635 633 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 22 25 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 123 126 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 640 643 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Supplementary Figure. HIV Env neutralization sensitivity to mAb b12 does not correlate neutralization sensitivity to sCD4. HIV luciferase reporter viruses were incubated with a range of concentrations of human mAb b12 or sCD4 1 h prior to infection of Cf2 cells transiently expressing CD4 and CCR5. Cells were harvested 48 h post infection and assayed for luciferase activity. Data are expressed as the concentrations at which luciferase expression was reduced by 50% compared to infection in the absence of mAb or sCD4 (IC50). (A) sCD4 IC50s were plotted as a function of b12 IC50s. R and p values, Spearman correlation. (B) sCD4 IC50s of HIV Envs with low to intermediate b12 sensitivity (< median; median = 3.374 mug/ml) were compared to Envs with intermediate to high b12 sensitivity (> median). p values, Mann-Whitney test.
###end p 30
###begin p 31
Click here for file
###end p 31
###begin title 32
Acknowledgements
###end title 32
###begin p 33
We thank Dennis Burton (Scripps) for providing the b12 and b6 antibodies. This work was supported by NIH grant MH83588. Core facilities were supported by Harvard University Center for AIDS Research and DFCI/Harvard Cancer Center grants.
###end p 33
###begin article-title 34
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Pathogenesis of macrophage tropic HIV-1
###end article-title 34
###begin article-title 35
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
###end article-title 35
###begin article-title 36
###xml 40 75 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Identification of shared populations of human immunodeficiency virus type 1 infecting microglia and tissue macrophages outside the central nervous system
###end article-title 36
###begin article-title 37
###xml 93 98 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection
###end article-title 37
###begin article-title 38
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
###end article-title 38
###begin article-title 39
Cell surface receptors, virus entry and tropism of primate lentiviruses
###end article-title 39
###begin article-title 40
###xml 95 130 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection
###end article-title 40
###begin article-title 41
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity
###end article-title 41
###begin article-title 42
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia
###end article-title 42
###begin article-title 43
###xml 63 66 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia
###end article-title 43
###begin article-title 44
###xml 129 164 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate
###end article-title 44
###begin article-title 45
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor
###end article-title 45
###begin article-title 46
###xml 23 58 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages
###end article-title 46
###begin article-title 47
###xml 29 32 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion
###end article-title 47
###begin article-title 48
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV vaccine design and the neutralizing antibody problem
###end article-title 48
###begin article-title 49
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
GP120: target for neutralizing HIV-1 antibodies
###end article-title 49
###begin article-title 50
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
###end article-title 50
###begin article-title 51
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Antibody neutralization and escape by HIV-1
###end article-title 51
###begin article-title 52
###xml 83 118 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate
###end article-title 52
###begin article-title 53
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain
###end article-title 53
###begin article-title 54
###xml 39 67 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 69 73 <span type="species:ncbi:12721">SHIV</span>
###xml 113 127 <span type="species:ncbi:9544">rhesus macaque</span>
Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease
###end article-title 54
###begin article-title 55
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop
###end article-title 55
###begin article-title 56
###xml 13 18 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors
###end article-title 56
###begin article-title 57
###xml 119 154 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
###end article-title 57
###begin article-title 58
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Preparation and characterization of human HIV type 1 neutralizing reference sera
###end article-title 58
###begin article-title 59
###xml 63 68 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structural definition of a conserved neutralization epitope on HIV-1 gp120
###end article-title 59
###begin article-title 60
###xml 28 63 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells
###end article-title 60
###begin article-title 61
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion
###end article-title 61
###begin article-title 62
###xml 116 121 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
###end article-title 62
###begin article-title 63
###xml 31 66 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 148 153 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome
###end article-title 63
###begin article-title 64
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 121 156 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
###end article-title 64
###begin article-title 65
###xml 6 11 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Broad HIV-1 neutralization mediated by CD4-binding site antibodies
###end article-title 65
###begin article-title 66
###xml 89 124 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
###end article-title 66
###begin article-title 67
###xml 73 108 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
###end article-title 67
###begin article-title 68
###xml 45 74 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses
###end article-title 68
###begin article-title 69
###xml 83 102 <span type="species:ncbi:9545">pig-tailed macaques</span>
###xml 135 164 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb
###end article-title 69
###begin article-title 70
###xml 71 86 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 146 175 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 176 179 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 196 200 <span type="species:ncbi:12721">SHIV</span>
###xml 220 225 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 240 246 <span type="species:ncbi:9606">humans</span>
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans
###end article-title 70

